Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.60 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409209 | 1.00 | REN (0.60) | RENALPIPKMPTGS1XIAP | |
| SCHEMBL27163859 | 1.00 | REN (0.60) | RENALPIPKMPTGS1XIAP | |
| SCHEMBL987955 | 0.95 | DPP7 (0.58) | RENDPP7 | |
| SCHEMBL16994019 | 0.95 | DPP7 (0.58) | RENDPP7 | |
| SCHEMBL12555472 | 0.94 | NAAA (0.59) | RENDPP7 | |
| SCHEMBL3159222 | 0.94 | NAAA (0.59) | RENDPP7 | |
| SCHEMBL8914221 | 0.94 | NAAA (0.59) | RENDPP7 | |
| SCHEMBL29129460 | 0.94 | NAAA (0.59) | RENDPP7 | |
| SCHEMBL8914559 | 0.94 | NAAA (0.59) | RENDPP7 | |
| SCHEMBL17941646 | 0.94 | NAAA (0.59) | RENDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4540239-A1 | CHIRAL SYNTHESIS OF NORNICOTINE AND NICOTINE | Siegfried AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024047152-A1 | CHIRAL SYNTHESIS OF NORNICOTINE AND NICOTINE | SIEGFRIED AG (CH) | 2024-03-07 | — | — | WO | disclosed |
| EP-4332098-A1 | CHIRAL SYNTHESIS OF NORNICOTINE AND NICOTINE | Siegfried AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023023513-A9 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | UNIVERSITY OF MASSACHUSETTS (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023023513-A1 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | UNIVERSITY OF MASSACHUSETTS (US) | 2023-02-23 | — | — | WO | disclosed |
| US-9255062-B2 | Fatty acid derivatives for oral administration endowed with high palatability | RHEA INNOVATIONS S.R.L. (IT) | 2016-02-09 | — | — | US | disclosed |
| CN-102105436-B | Oral fatty acid derivatives endowed with high palatability | BERNI CANANI ROBERTO | 2014-11-12 | — | — | CN | disclosed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | disclosed |
| CN-102105436-A | Oral fatty acid derivatives endowed with high palatability | ROBERTO BERNI CANANI | 2011-06-22 | — | — | CN | disclosed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | disclosed |
| EP-2268605-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PAIA- TABILITY | Berni Canani, Roberto (IT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009130735-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2009-10-29 | — | — | WO | disclosed |
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | FABP2, FFAR2, VIP | REN 1169/4885ALPI 328/4885PKM 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.